2006
Use of Novel Second-Line Targeted Therapies in Non–Small Cell Lung Cancer
Massarelli E, Herbst RS. Use of Novel Second-Line Targeted Therapies in Non–Small Cell Lung Cancer. Seminars In Oncology 2006, 33: 9-16. PMID: 16472704, DOI: 10.1053/j.seminoncol.2005.12.007.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerOverall response rateEpidermal growth factor receptorCell lung cancerLung cancerResponse rateSecond-line therapeutic approachStandard cytotoxic regimensFirst-line treatmentNew treatment optionsLung cancer casesQuality of lifeNew chemotherapeutic agentsCytotoxic regimensGrowth factor receptorRefractory settingMetastatic diseaseRefractory diseaseLocal therapyNSCLC treatmentTreatment optionsCancer deathTargeted therapyTreatment outcomesCancer cases
2000
Vinorelbine and Gemcitabine Combinations in Advanced Non–Small-Cell Lung Cancer
Lilenbaum R, Herbst R. Vinorelbine and Gemcitabine Combinations in Advanced Non–Small-Cell Lung Cancer. Clinical Lung Cancer 2000, 2: 123-127. PMID: 14731322, DOI: 10.3816/clc.2000.n.024.Peer-Reviewed Original ResearchAdvanced non-small cell lung cancerNon-small cell lung cancerLung cancerSmall cell lung cancerPoor performance statusTaxane-based regimensVinorelbine/gemcitabinePlatinum-based regimensSingle-agent activityTreatment of patientsOverall response rateNew chemotherapeutic agentsNonoverlapping toxicitiesGemcitabine combinationElderly patientsPerformance statusRandomized studyResponse rateWeekly scheduleChemotherapeutic agentsVinorelbineRegimensGemcitabinePatientsRegimen